ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

DOW JONES NEWSWIRES A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx. In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation. Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes. "The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement. In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations. Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
04/10/201409:43:48Merck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial...
04/10/201409:30:24Merck: Hepatitis C Drug Shows 98% Cure Rate in Trial
04/10/201409:09:09Merck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial
03/30/201408:46:34MARKET SNAPSHOT: Play-it-safe Stock Investors May Take Some Risk...
03/30/201408:44:49New Drugs to Lower Cholesterol Show Promise: Studies
03/28/201418:57:23Merck CEO Frazier: Consumer Unit Draws 'Substantial' Interest...
03/27/201409:44:41U.S. Hot Stocks: Hot Stocks to Watch
03/26/201416:30:44Merck, Glaxo Hold Off on Help With Affordable Care Act Copays
03/12/201415:50:24Glaxo Reports Positive Results from Asthma Drug Studies
03/12/201415:36:51GlaxoSmithKline Reports Positive Results from Asthma Drug Studies...
03/05/201414:00:05Merck, Bristol-Myers Report Positive Data
03/05/201413:50:39Merck, Bristol-Myers Report Positive Data on Investigational...
02/12/201418:27:22Merck's Sale of Consumer Business Could Fetch $10 Billion...
02/07/201417:50:50Merck to Settle Contraceptive Product Lawsuits
02/07/201417:30:19Merck to Settle Contraceptive Product-Liability Lawsuits
02/07/201411:50:13Merck to Pay $100 Million in Legal Settlement on Contraceptive...
02/05/201416:47:03MARKET SNAPSHOT: U.S. Stocks Fall; Data Stoke Fears Of Slowdown
02/05/201414:11:17MARKET SNAPSHOT: U.S. Stocks Eye Rebound; Dow Reverses Losses
02/05/201411:42:07MARKET SNAPSHOT: U.S. Stocks Fall To Session Lows After ISM...
02/05/201410:13:00MARKET SNAPSHOT: U.S. Stocks Open Lower On Weak ADP Report

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad